Lipella Pharmaceuticals Inc.
LIPO
$0.31
$0.0311.80%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.01% | -33.26% | -8.18% | -8.60% | 0.71% |
| Total Depreciation and Amortization | 0.00% | -9.68% | 16.67% | 64.71% | 180.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -90.71% | -49.40% | -67.63% | -35.69% | -41.34% |
| Change in Net Operating Assets | 258.90% | 212.22% | 253.28% | 1,358.89% | -287.17% |
| Cash from Operations | -29.49% | -20.90% | -15.25% | -25.41% | -38.95% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 100.91% | 237.17% | 237.17% | 76.33% | -46.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.53% | 236.61% | 291.14% | 112.61% | -46.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 147.52% | 182.78% | 210.78% | 39.34% | -146.02% |